Danaher (NYSE:DHR) Q4 2025 Earnings call January 28, 2026 08:00 AM ET Company ParticipantsDoug Schenkel - Managing Director of Life Science Tools and DiagnosticsJohn Bedford - VP of Investor RelationsMatt McGrew - EVP and CFOMichael Ryskin - Managing DirectorPatrick Donnelly - Managing DirectorRainer Blair - President and CEOScott Davis - Chairman and CEOTycho Peterson - Managing Director of Global EquitiesConference Call ParticipantsDan Brennan - Senior Equity Research Analyst and Managing DirectorDan Leon ...

Danaher Corporation (NYSE:DHR) is one of the stocks in focus as Jim Cramer shared his weekly game plan. Cramer expects positive things from the company’s upcoming quarterly earnings report, as he remarked: CNBC Investing Club members, look out. You’re going to be flooded with emails Wednesday because Charitable Trust holdings, Danaher, Starbucks, GE Vernova, Microsoft, Meta, and Corning all report. Let me give you a preview. After a multi-year dry spell, Danaher has big orders from biotechs for expensive ...

Repligen Corporation (NASDAQ:RGEN) is one of the best mid-cap growth stocks to buy right now. On January 16, UBS raised the firm’s price target on Repligen to $200 from $190, while maintaining a Buy rating. The firm believes that Repligen is uniquely positioned to lead a sustained recovery in the bioprocessing sector, supported by its diversified growth drivers and the accelerating reshoring trend. With over 20% order growth and an expanding footprint in Edge manufacturing, the firm sees Repligen as a core ...

Company Overview - Repligen is headquartered in Waltham, Massachusetts and employs approximately 2,000 people [2][3] - The company focuses on bioprocessing and has dual manufacturing capabilities in the U.S. and Europe [3] Financial Guidance - For 2025, Repligen projects sales to reach USD 733 million at the midpoint of their guidance [3] Vision and Strategy - The company's vision is to be the global leader in bioprocessing innovation, offering a diverse portfolio of data-driven solutions across various therapeutic modalities [4] - Innovation has been a key focus for Repligen over the past decade, positioning the company in a large bioprocessing market with significant competition [5]

Repligen FY Conference Summary Company Overview - **Company**: Repligen (NasdaqGS:RGEN) - **Headquarters**: Waltham, Massachusetts - **Employees**: Approximately 2,000 - **Sales Guidance for 2025**: $733 million at midpoint [2][24] Core Industry Insights - **Industry Focus**: Bioprocessing - **Market Size Growth**: Total addressable market increased from $3 billion to $13 billion over six years, indicating significant growth potential [8] - **Market Share**: Repligen currently holds about 2% of the market, suggesting substantial runway for growth [9] Key Strategic Points - **Innovation**: Central to Repligen's strategy, with a focus on breakthrough solutions to enhance yield and cost structure for customers [3][5] - **Product Portfolio**: Diverse offerings across four main franchises: filtration, chromatography, analytics, and proteins, with approximately 80% of the portfolio having little to no competition [5][6] - **Growth Strategy**: Aiming for 30% EBITDA margin by 2030, with a commitment to outpace market growth by 5 percentage points [25][26] Financial Performance and Projections - **Historical Growth**: CAGR of 18% from 2019 to 2025, excluding COVID-19 impacts [7] - **2026 Growth Expectations**: Targeting 11%-12% top-line growth, factoring in 200 basis points of headwinds from a specific gene therapy drug [34] - **Margin Expansion**: Current EBITDA margin at 19%, with plans to reach 30% by 2030 through operational efficiencies and strategic investments [26][37] Market Dynamics - **Customer Diversification**: Shift from reliance on top customers; top 10 customers now account for one-third of business compared to two-thirds a decade ago [10] - **Geographical Focus**: Currently, only 17% of sales come from Asia, with plans to enhance presence in this region [22] - **New Modalities**: Despite headwinds in 2025, new modalities are expected to rebound and contribute to growth from 2027 onwards [46] Product Development and Innovation - **Recent Launches**: Three significant product launches in 2025, including a new version of the protein concentration tool and single-use mixers [31] - **Upgrade Cycle**: Ongoing upgrade cycle for SoloVPE systems, with only a small percentage of the installed base upgraded so far, indicating future revenue potential [50] - **ATF Systems**: Anticipated growth in ATF systems, with over 50 late-stage and commercial drugs utilizing this technology [52] Competitive Positioning - **Reshoring Opportunities**: Repligen is well-positioned to compete for reshoring-related contracts due to its U.S. manufacturing capabilities and competitive pricing advantages [43] - **Key Account Management**: Focus on deepening relationships with existing key accounts, increasing product offerings per account by 2.5 times over five years [14][56] Future Outlook - **Strategic Investments**: Continued investment in R&D (6%-7% of sales) and infrastructure to support growth and operational efficiency [27][28] - **Market Trends**: Positive outlook on new modalities, particularly in cell therapy and gene therapy, with ongoing product launches to support these areas [47] - **Overall Sentiment**: Management expresses strong optimism for 2026 and beyond, highlighting numerous growth opportunities across various segments [59]

Company Overview - Repligen is a pure-play bioprocessing company aiming to be the global innovation leader in the field [5, 7] - The company's revenue for FY25 is guided at $733 million [8] Growth and Market Position - Repligen has experienced an 18% Compound Annual Growth Rate (CAGR) in revenue since 2019, growing from $270 million to $733 million in 2025 [19] - The company operates in a large and growing bioprocessing market, estimated to be over $20 billion [22] - Repligen's Total Addressable Market (TAM) has significantly expanded from ~$3 billion in 2019 to $13 billion+ in 2025 [23] Diversification and Innovation - The top 10 customers account for 35% of revenue in 2025, indicating a diversified customer base [28] - New modalities represent 16% of revenue in 2025, compared to 5% in 2015, showing diversification in therapeutic areas [28] - Approximately 80% of Repligen's portfolio is differentiated, with new product introductions driving growth [43] - Revenue contribution from products launched in the trailing three years is approximately 10% in 2025 [46] Financial Targets and Margins - The company is targeting a ~30% adjusted EBITDA margin [11, 67] - Repligen anticipates a mid-teens revenue CAGR, driven mostly by organic growth, with modest M&A activity [63] - For FY25, revenue is projected to be between $729 million and $737 million, representing a reported growth of 15%-16% [84]

Core Viewpoint - Repligen Corporation has announced the election of Dr. Martin D. Madaus as Chair of the Board, effective March 13, 2026, following the retirement of Tony Hunt as Executive Chair [1][2] Group 1: Leadership Transition - Tony Hunt is retiring from his role as Executive Chair and member of the Board of Directors effective March 13, 2026, but will continue to serve as an advisor until March 2027 [1][2] - Dr. Martin D. Madaus, who has been a director since February 2023, has extensive industry experience, including leadership roles at Millipore Corporation [2][3] - Olivier Loeillot, President and CEO of Repligen, expressed confidence in the leadership transition, highlighting the strong foundation laid by Hunt and the qualifications of Madaus [2] Group 2: Company Overview - Repligen Corporation is a global life sciences company focused on developing and commercializing innovative bioprocessing technologies for the manufacturing of biological drugs [3] - The company serves biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide, with a focus on areas such as Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins [3] - Repligen's headquarters are located in Waltham, Massachusetts, with manufacturing sites primarily in the U.S. and additional key locations in Estonia, France, Germany, Ireland, the Netherlands, and Sweden [3]

Core Viewpoint - Kinney Asset Management has significantly increased its investment in Avantor, making it the fund's largest equity position despite the company's recent financial struggles and stock price decline [1][2][3]. Group 1: Investment Activity - Kinney Asset Management disclosed a purchase of 470,000 shares of Avantor, increasing its position by approximately $4.52 million [1][2]. - The total position in Avantor now stands at about 1.85 million shares, valued at $23.03 million, representing 34.3% of the fund's reportable assets under management (AUM) [2][3]. Group 2: Company Financials - Avantor's stock price is currently $11.52, down 46% over the past year, underperforming the S&P 500, which has increased by about 16.5% during the same period [3]. - The company reported a revenue decline of 5% to $1.62 billion in the third quarter, primarily due to reduced demand in the biopharma sector [6]. - Avantor experienced a significant non-cash goodwill impairment of $785 million related to its distribution business, but still generated $268 million in adjusted EBITDA and $172 million in free cash flow [8]. Group 3: Company Overview - Avantor, Inc. is a global provider of essential products and services for the life sciences and advanced technology sectors, focusing on laboratory consumables and bioprocessing solutions [5]. - The company serves a diverse range of customers, including biopharma, healthcare, education, government, and advanced technology sectors across multiple regions [7]. Group 4: Management Outlook - Management has expressed optimism through restructuring efforts and a $500 million share repurchase program, indicating confidence in the company's future despite current challenges [9]. - The investment strategy of Kinney Asset Management suggests a focus on long-term recovery and normalized earnings potential for Avantor, rather than short-term fluctuations [10].

Core Viewpoint - Repligen Corporation will participate in the J.P. Morgan 2026 Healthcare Conference, highlighting its focus on bioprocessing technology leadership [1]. Group 1: Company Overview - Repligen Corporation is a global life sciences company that develops and commercializes innovative bioprocessing technologies and systems for manufacturing biological drugs [3]. - The company serves biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide [3]. - Key focus areas include Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins [3]. - The corporate headquarters is located in Waltham, Massachusetts, with manufacturing sites primarily in the U.S. and additional sites in Estonia, France, Germany, Ireland, the Netherlands, and Sweden [3]. Group 2: Conference Participation - Olivier Loeillot, President and CEO, will present an overview of the company on January 13 at 2:15 p.m. PT during the conference [1]. - A live webcast of the conference presentations will be available on Repligen's Investor Relations website, with a replay accessible for a limited time after the event [2].

Group 1 - Sands Capital Global Growth Fund reported a -2.0% return in Q3 2025, underperforming the MSCI ACWI which returned 7.6% [1] - The fund adopts a flexible approach to identify promising growth companies globally, with a focus on concentrated leadership in global equities [1] Group 2 - Repligen Corporation (NASDAQ:RGEN) is highlighted as a key stock, with a one-month return of 1.94% and a 52-week gain of 7.30% [2] - As of December 16, 2025, Repligen's stock closed at $158.09, with a market capitalization of $8.899 billion [2] Group 3 - Repligen is recognized as a leading supplier of bioprocessing tools for biologic drug manufacturing, but its business is heavily dependent on the health of its end markets [3] - The company has experienced a 20% revenue decline and a 65% contraction in adjusted operating income through 2024, with signs of recovery in 2025 [3] - Despite expectations for a "classic growth" profile, Repligen's profitability remains below pre-COVID levels, leading to a decision to reallocate capital due to its elevated valuation and small portfolio weight [3]